1. 1840PPreclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. (23rd October 2018) Authors: Brett, S; Yadavilli, S; Seestaller-Wehr, L; Bhattacharya, S; Jackson, H; Bi, M; Willoughby, J; Zhang, T; Liu, Y-B; Katlinskaya, Y K; Shi, H; Jing, J; Hahn, A; Speller, S; David Figueroa, D; Yu, J; Olive, D; Cragg, M; Mayes, P; Hoos, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 299 The prevalence and role of SCN10A variants in Han Chinese patients with Brugada syndrome: the SADS-TW BrS registry. (13th January 2020) Authors: Chen, C-Y; Liu, Y-B; Lu, T-P; Yu, Q-Y; Lin, L-Y; Yu, C-C; Makita, N; Ishikawa, T; Lai, L-P; Hwang, J-J; Yeh, S-F; Lin, J-L; Juang, J-M; Horie, M; Antzelevitch, C Journal: European heart journal Issue: Volume 41:(2020)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Oxymatrine suppresses proliferation and induces apoptosis of hemangioma cells through inhibition of HIF-1a signaling. (June 2015) Authors: Fei, Z-W; Qiu, M-K; Qi, X-Q; Dai, Y-X; Wang, S-Q; Quan, Z-W; Liu, Y-B; Ou, J-M Journal: International journal of immunopathology and pharmacology Issue: Volume 28:Number 2(2015) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗